{"preliminary_commentary":{"by_channel":{"x_thread":9},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06362395\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[],"indication":"liver metastases","name":"ULTRAS","nct_id":"NCT06362395","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ultras-nct06362395. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ULTRAS","arms":[{"description":"Magnetic resonance (MR)-guided stereotactic ablative single-fraction with high dose radiation (27Gy)","label":"MRL adaptive high dose","type":"EXPERIMENTAL"},{"description":"Magnetic resonance (MR)-guided stereotactic ablative single-fraction with ultra-high dose radiation (38Gy)","label":"MRL adaptive ultra-high dose","type":"OTHER"}],"collaborators":[],"completion_date":{"date":"2031-09","type":"ESTIMATED"},"conditions":["Liver Metastases"],"enrollment":{"count":114,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Magnetic resonance (MR)-guided stereotactic ablative single-fraction (SBRT)","otherNames":[],"type":"RADIATION"}],"last_update":"2026-03-04","lead_sponsor":"University Health Network, Toronto","official_title":"Ultra-high Dose Radiation for Liver Metastasis Using MR-guided TReatment With Stereotactic Ablative Single-fraction","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2031-09","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Local control (LC) of treated target lesion compared to high dose MR-guided stereotactic single-fraction radiation.","timeFrame":"5 years"}],"references":[{"citation":"Wong H, Ng SSW, Mohamad I, Alborz J, Stanescu T, Liu ZA, De Leon J, Tan H, Ng SP, Radhakrishna G, Bahij R, Intven M, Kirichenko A, Mesci A, Yan M, Dawson L, Augilera T, Hosni A. Ultra-high dose radiation for Liver metastasis using MR-guided TReatment with stereotactic Ablative Single-fraction (ULTRAS): study protocol for a phase III randomized controlled trial. Contemp Clin Trials. 2026 Aug;167:108381. doi: 10.1016/j.cct.2026.108381. Epub 2026 Jun 17.","pmid":"42309387","type":"DERIVED"}],"start_date":{"date":"2024-12-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Ultra-high Dose Radiation for Liver Metastasis Using MR-guided TReatment With Stereotactic Ablative Single-fraction","url":"https://clinicaltrials.gov/study/NCT06362395"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ultras-nct06362395"}